Life sciences, Capital Markets Executive & Investment Committee Member

Dr Graeme Wald has over 25 years’ experience in the life science and capital markets industries. He was the top rated analyst in the Pharmaceutical sectors in both South Africa and Australia while employed as an equities analyst by Merill Lynch and Wilson HTM respectively. 

​While at Wilson HTM he played a key role in building the company’s life science business into the top rated life science broker in Australia as measured by number of IPO’s, secondary raising phases and value of capital raised (approx. $750M). After leaving Wilson HTM Graeme worked at BioScience Managers and OneVentures. At OneVentures he was a Partner in Fund III, the company’s largest fund, where he was responsible for bringing in 50% of the investments. 

​He was founding Chairman of Prota Therapeutics and a member of the Board of NASDAQ listed Nexvet, where he was also chairman of the Risk and Audit committee. Graeme worked as a research chemist in the US, South Africa and Israel.

​Graeme has a PhD in Chemistry, an MBA and is a Graduate of the Australian Institute of Company Directors.